Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Public ClinicalTrials.gov record NCT07021066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT07021066
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- SystImmune Inc.
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- BL-M05D1 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2025
- Primary completion
- Feb 27, 2027
- Completion
- May 30, 2027
- Last update posted
- Apr 29, 2026
2025 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Cancer Center- Phoenix | Phoenix | Arizona | 85054 | Recruiting |
| HonorHealth | Scottsdale | Arizona | 85266 | Recruiting |
| University of Colorado Health | Aurora | Colorado | 80045 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06510 | Recruiting |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Not yet recruiting |
| Sarah Cannon Research Institute - Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | Not yet recruiting |
| NEXT Oncology- Austin | Austin | Texas | 78758 | Recruiting |
| NEXT Oncology- Dallas | Dallas | Texas | 75039 | Recruiting |
| MD Anderson | Houston | Texas | 77030 | Not yet recruiting |
| NEXT Oncology San Antonio | San Antonio | Texas | 78229 | Recruiting |
| START Center for Care Center- San Antonio | San Antonio | Texas | 78229 | Not yet recruiting |
| Baylor Scott and White Medical Center- Temple Clinic | Temple | Texas | 76504 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07021066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07021066 live on ClinicalTrials.gov.